RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner status, long-term investment preference, and available capital, ResMed Inc (RMD) is not an optimal buy at this moment. The stock is currently in an oversold state with bearish technical indicators, and no strong positive catalysts or trading signals are present to suggest immediate upside potential. While the company's financial performance is solid, the technical and sentiment data indicate that waiting for a better entry point may be more prudent.
The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The RSI indicates oversold conditions (17.571), and MACD is below 0 with negative contraction (-1.228). Key support levels are at 221.509 and 217.638, while resistance levels are at 227.773 and 234.038. The stock is trading below the pivot point of 227.773.
The company reported strong Q2 financials with double-digit revenue and earnings growth, as well as improved gross margins. Analysts have raised price targets, with some maintaining a Buy or Outperform rating.
No recent news or significant trading trends from hedge funds or insiders. The stock's technical indicators are bearish, and options data suggests negative sentiment. Additionally, the stock has a 20% chance of declining in the short term based on candlestick pattern analysis.
In Q2 2026, ResMed reported a 10.98% YoY increase in revenue to $1.42 billion, a 13.92% YoY increase in net income to $392.59 million, and a 14.53% YoY increase in EPS to $2.68. Gross margin improved to 60.93%, up 5.52% YoY, indicating strong financial health and operational efficiency.
Analyst sentiment is mixed. While some analysts (e.g., Citi, RBC Capital, KeyBanc) maintain Buy or Outperform ratings with raised price targets (up to $345), others (e.g., Piper Sandler, Baird, Stifel) remain Neutral or Hold, citing modest growth and some concerns despite strong Q2 results.
